# Suven Life Sciences Ltd (SUVEN)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹269.52
Day Change: +0.2%
52W High: ₹299.99
52W Low: ₹124.11
Market Cap: ₹6,661 Cr

## Valuation
P/E: 0
P/B: 19.95
EPS: ₹-12.31
Book Value: ₹12.66
Dividend Yield: 0%

## Returns
1Y Return: 34.35%

## Profitability
ROE: -78.8%
ROCE: 0%
Debt/Equity: 0.03
Revenue Growth: 465.6%
Profit Growth: 0%
EBITDA Margin: 0%
Operating Margin: -547.58%

## About
Suven Life Sciences Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Suven Life Sciences Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:05.656Z
Price History Updated: 2026-05-18T22:58:33.912Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:33.912Z
Quant Updated: 2026-05-18T22:58:33.912Z
Sentiment Updated: 2026-05-18T22:58:33.912Z
Financials Status: current
Financials Updated: 2026-05-18T13:30:40.945Z
Financials Last Attempt: 2026-05-18T13:30:40.945Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹521 Cr
Operating Profit: ₹159 Cr (OPM 31%)
Net Profit: ₹109 Cr
Tax: ₹152 Cr

## Annual P&L History
Mar 2016: Rev ₹521Cr | PAT ₹109Cr | OPM 31%
Mar 2017: Rev ₹499Cr | PAT ₹72Cr | OPM 20%
Mar 2018: Rev ₹543Cr | PAT ₹87Cr | OPM 24%

## Balance Sheet (Mar 2016)
Total Assets: ₹773 Cr
Total Liabilities: ₹773 Cr
Borrowings: ₹109 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Venkateswarlu  Jasti M.Pharm. M.S., CEO, MD & Executive Chairman
- N. V. S. Ramakrishna M.Sc, Ph.D., President & Chief Scientific Officer
- Sudharani  Jasti B.Sc., Whole-Time Director
- M. Mohan Kumar C.M.A., Chief Financial Officer
- Sangeetha Laxmi Kandari, Company Secretary & Compliance Officer

---
Source: rupiya.io/stocks/suven
Disclaimer: For research and education only. Not investment advice.